![]() |
LOL Joe. Nice.
|
Quote:
Fund manager. LMAO! I had to edit this...since I just read the whole paragraph where the Fund Manager (lmao) states that "(Cramer's) principles and ideas are no different than what any other knowledgeable broker/manager would advise any of his retail investors" Joe, I was advised not to feed you. I'm taking that advice, you reek of absurdity. |
Joe is an equity trader... never said he was a fund manager.
You are an IT Consultant... so who are you to give investment advice? You come in and tell us that the premise of this thread is stupid, because you've read books that "prove" it. Like RCZ, how is that productive? If you want to discuss your portfolio theory, start another thread. It's pretty damn simple. |
Quote:
Probably a good time to leave this thread to the fund manager and Cramerica. :bowrofl: |
Quote:
Since your reading comprehension is at a level far above mine, can you perhaps point out where I said I was a fund manager? Good luck with that. Oh, and BTW...pat yourself on the back for dwelling on one of my very rare typographical errors. Having to nit-pick on such a level is certainly a sign of a strong argumentative stance on your position. :tup: MODS: Please fell free to clean up this thread, but please don't lock/delete it. It would be a shame for this topic to go to waste, although it would be beneficial to start a new thread...perhaps with an age-requirement for entry? |
LOL, bye Troll
:tiphat: |
Quote:
We now leave this thread to the line-chasers, as they cannot handle constructive criticism. Mebbe I start a thread about how to "invest" and not "speculate". Y'all are welcome to join it and flame the living crap out of me. Lilly swings to profit, raises forecast BOSTON (MarketWatch) -- Eli Lilly & Co. said Wednesday it swung to a third-quarter profit after solid sales in the 2009 quarter as well as year-earlier litigation charges related to its drug Zyprexa. Lilly (LLY) posted net income of $941.8 million, or 86 cents a share. In the year-ago period it lost $465.6 million, or 43 cents a share. Last year's quarter featured a charge of $1.48 billion associated with litigation over its psychiatric drug Zyprexa. This year's quarter contained a charge of $425 million related to the sale of its Tippecanoe, Ind., facility to chemical-maker Evonik Laboratories AG. Excluding various items, Lilly (LLY) would have reported adjusted earnings of $1.20 a share versus the year-earlier 98 cents. Revenue for the quarter rose 7% to $5.56 billion. Lilly's results topped Wall Street estimates. A poll of analysts by FactSet Research pegged Lilly at posting earnings of $1.02 a share, on revenue of $5.41 billion. Lilly's positive report prompted the company to raise its financial forecast for the year. The company said that it now expects full-year adjusted earnings of $4.30 to $4.40 a share, compared to its previous forecast of $4.20 to $4.30 a share. Reported earnings per share should come in between $3.90 and $4.00. Analysts were expecting a profit of $4.29 a share, according to FactSet. Sales of the company's best-selling product, the psychiatric drug Zyprexa, were $1.22 billion, up 3%. Sales of the antidepressant Cymbalta, its second best-seller, rose 10% to $790 million. The company's diabetes product Humalog saw sales climb 16% to $500 million, while sales of the oncology product Alimta took in sales of $462 million, up 47%. |
Hope it now makes sense to others why I covered yesterday.
Bought AAPL pre-market today at $199.41 and sold a little too soon at $205.29. Got back in at $204.83 where I'm holding my current position. Stop is set at $206.50, sell on a 0.5% break-out of today's range. AAPL is one of the easiest stocks to trade around earnings. |
Quote:
Trading is not about making a speculative "quick buck." Those who treat the markets like a casino usually come out short in the end. Properly executed trades can essentially multiply long-term growth. Of course I have investments which are managed by other professionals that I don't need to watch on a daily basis, but even an abnormally high 40% yearly return on an investment doesn't compare to 1-1.5% daily returns from trading. A perfect example of this is AAPL, one of the few stocks I can mention as my firm holds no current position. I was just stopped out and I still booked a sizeable profit between yesterday and today. Go back and monitor my trades. |
Quote:
I can't really say you're full of it, nor can I say your trades are real. All I know is, folks that claim to make 1-2% daily via trading rank very low on my Veracif!er BS Scale. Very low. Take for example a post I made on my new thread. Quote:
It's all real-time. I'll check it's performance every now and then, no worries. I suppose if I was about to retire the current market would be a drag. I took a nice hit last year. I'm sure you did extraordinarily well, of course. I used the opportunity to move a lot more money into stocks, and I focused on cash-flow, low-debt, high dividend yield large caps. I guess time will tell. I'm a patient investor. And Joe, you are no Goldman-Sachs. |
Thanks for ruining the thread 370zsteve. You have been so useful. Mods Can we please get a clean up....
Just let him talk guys, **** him. Lets keep this thread on track. That damn downgrade of wfc made a mess in my portfolio today. |
Holy crap this thread got shat on! lol... thats what you get when you are away from the 370 world for more than 2 days lol... Anyhow - Anytime you respond to media telling you to buy / sell... you have to remember that other people will react faster than you... which is why you try and make those predictions BEFORE they announce it... there is risk associated with everything...
|
Quote:
|
Its ok, keep talking.
Good afternoon for the market today. |
Quote:
|
All times are GMT -5. The time now is 10:40 PM. |
Powered by vBulletin® Version 3.8.4
Copyright ©2000 - 2025, Jelsoft Enterprises Ltd.
Search Engine Optimization by vBSEO 3.6.0 PL2